Today: 1 May 2026
CrowdStrike stock price slips into earnings week as CRWD rolls out FalconID, draws fresh target cut

CrowdStrike stock price slips into earnings week as CRWD rolls out FalconID, draws fresh target cut

New York, Feb 28, 2026, 15:27 (EST) — The session ended with markets closed.

CrowdStrike Holdings dropped 2.39% to close at $371.98 on Friday, breaking a two-session climb as markets pulled back. Trading volume picked up, reaching roughly 5.1 million shares—topping the 50-day average. The stock sits about 34% off its November 52-week high.

U.S. markets will stay closed Saturday, and heading into Monday, investors remain skittish about high-growth software names after February’s selloff battered both tech and financials. “We were reminded there are still some cracks out there,” said Ryan Detrick, chief market strategist at Carson Group, flagging stronger inflation numbers as yet another setback for those betting on rate cuts in the near term. Reuters

Cybersecurity stocks continue to face headline pressure as companies hold budgets steady. Zscaler, which competes with CrowdStrike, reported a larger net loss for the quarter due to increased spending. The stock dropped roughly 9% after hours. Still, CEO Jay Chaudhry insisted, “AI is driving demand for security.” Reuters

Jefferies slashed its price target on CrowdStrike to $500 from the previous $600 but maintained its Buy call. Analyst Joseph Gallo noted that their field checks suggest CrowdStrike is on track to outperform consensus on fourth-quarter annual recurring revenue, a crucial subscription metric in software.

CrowdStrike dropped some product updates this week, rolling out FalconID for general use. The new tool brings phishing-resistant multi-factor authentication (MFA) into the Falcon platform. “Traditional MFA is architecturally broken,” said Chief Technology Officer Elia Zaitsev, who claims their system links authentication to real-time risk signals instead of relying on static prompts. CrowdStrike

CrowdStrike plans to hold its Fal.Con Gov gathering on March 18 in Washington, D.C., framing the event as a meeting point for public-sector security leaders navigating what it calls an “AI threat era.” “Defending the nation requires real-time intelligence,” said President Michael Sentonas. CrowdStrike

The company plans to present at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco on March 5. Investors can catch the webcast on its investor relations page.

Still, there’s risk in the mix. Earlier this week, cybersecurity stocks faltered—investors zeroed in on Anthropic’s Claude Code Security tool and what it might mean for the sector. CrowdStrike took a roughly 11% hit during that selloff. The conversation now boils down to one thing: is AI going to spur new threats and push security budgets higher, or will automation from tools like this squeeze growth and pricing power?

Next up: CrowdStrike is set to report its Q4 and full-year numbers after the bell on Tuesday, March 3, with the conference call locked in for 5:00 p.m. Eastern. Traders will zero in on the company’s outlook and any color on subscription momentum, especially ARR trends heading toward fiscal 2027.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:13 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Chevron stock price faces Monday test after Leviathan shutdown, Hormuz shipping risks
Previous Story

Chevron stock price faces Monday test after Leviathan shutdown, Hormuz shipping risks

AST SpaceMobile stock drops into weekend as Vodafone’s Europe satellite venture goes live
Next Story

AST SpaceMobile stock drops into weekend as Vodafone’s Europe satellite venture goes live

Go toTop